A new suite of studies from the Pan Cancer Analysis of Whole Genomes (PCAWG) Consortium provides the most detailed resolution of cancer genomes to date, extending our knowledge of driver genes, mutational features, structural alterations and more. Kreisberg, Ideker, Mills and Meric-Bernstam discuss the foundational and translational insights gained from this project.
Subscribe to Journal
Get full journal access for 1 year
only $8.67 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Hoadley, K. A. et al. Cell 173, 291–304.e6 (2018).
International Cancer Genome Consortium. et al. Nature 464, 993–998 (2010).
ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium. Nature 578, 82–93 (2020).
Zhang, W. et al. Nat. Genet. 50, 613–620 (2018).
Melton, C., Reuter, J. A., Spacek, D. V. & Snyder, M. Nat. Genet. 47, 710–716 (2015).
Hofree, M. et al. Nat. Commun. 7, 12096 (2016).
Reyna, M. A. et al. Nat. Commun. 11, 729 (2020).
Rheinbay, E. et al. Nature 578, 102–111 (2020).
Paczkowska, M. et al. Nat. Commun. 11, 735 (2020).
Shuai, S., Gallinger, S. & Stein, L. Nat. Commun. 11, 734 (2020).
Jiao, W. et al. Nat. Commun. 11, 728 (2020).
Yakneen, S. et al. Nat. Biotechnol. https://doi.org/10.1038/s41587-019-0360-3 (2020).
Gerstung, M. et al. Nature 578, 122–128 (2020).
PCAWG Transcriptome Core Group. Nature 578, 129–136 (2020).
Lui, G. Y. L., Grandori, C. & Kemp, C. J. J. Clin. Pathol. 71, 957–962 (2018).
G.B.M. is on the scientific advisory board or is a consultant for AstraZeneca, Chrysallis Biotechnology, ImmunoMET, Ionis, Lilly, PDX Pharmaceuticals, Signalchem Lifesciences, Symphogen and Tarveda; has stock, options or other financial interests in Catena Pharmaceuticals, ImmunoMet, SignalChem and Tarveda; has a licensed technology HRD assay to Myriad Genetics, and DSP patents with Nanostring; has research sponsored by Nanostring Center of Excellence and Ionis (provision of tool compounds only). F.M.-B is on the scientific advisory board or is a consultant for Immunomedics, Inflection Biosciences, Mersana Therapeutics, Puma Biotechnology, Seattle Genetics, Silverback Therapeutics, Spectrum Pharmaceuticals, Aduro BioTech, DebioPharm, eFFECTOR Therapeutics, F. Hoffman-La Roche, Genentech, IBM Watson, Jackson Laboratory, Kolon Life Science, OrigiMed, PACT Pharma, Parexel International, Pfizer, Samsung Bioepis, Seattle Genetics, Tyra Biosciences, Xencor and Zymeworks; has research sponsored by Aileron Therapeutics, AstraZeneca, Bayer Healthcare Pharmaceutical, Calithera Biosciences, Curis Inc., CytomX Therapeutics, Daiichi Sankyo, Debiopharm International, eFFECTOR Therapeutics, Genentech, Guardant Health, Millennium Pharmaceuticals, Novartis, Puma Biotechnology and Taiho Pharmaceutical; and receives honoraria from Chugai Biopharmaceuticals, Mayo Clinic, Rutgers Cancer Institute of New Jersey and UT Health San Antonio. T.I. is co-founder of and has an equity interest in Data4Cure; and has an equity interest in Ideaya BioSciences; the terms of this arrangement have been reviewed and approved by the University of California, San Diego in accordance with its conflict of interest policies.
About this article
Cite this article
Kreisberg, J.F., Ideker, T., Meric-Bernstam, F. et al. Prospecting whole cancer genomes. Nat Cancer 1, 273–275 (2020). https://doi.org/10.1038/s43018-020-0045-3